Directs the state board of pharmacy to annually identify up to fifteen prescription drugs with increased costs and provide the list to the attorney general to obtain reasons for the cost increases.
Regulates price increases for prescription drugs.
Requires prescription drug manufacturers to file a detailed, updated list of each pharmaceutical sales representative engaged by the manufacturer and to pay an annual fee for each name listed with the department of business regulation.
Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
Requires pharmacy benefit managers to reimburse pharmacist no less than national drug acquisition costs plus fee.
Requires pharmacy benefit managers to reimburse pharmacist no less than national drug acquisition costs plus fee.
Establishes a process whereby large drug manufacturers, may be penalized for prescription drug price increases where there is no, or inadequate, new evidence to support the price increase.
Sets controls on Medicaid prescription drug costs by imposing transparency and accountability requirements on managed care organizations (MCOs) and their pharmacy benefit managers (PBMs).
Sets controls on Medicaid prescription drug costs by imposing transparency and accountability requirements on managed care organizations (MCOs) and their pharmacy benefit managers (PBMs).